These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20613720)

  • 1. Clinical trial simulation: a review.
    Holford N; Ma SC; Ploeger BA
    Clin Pharmacol Ther; 2010 Aug; 88(2):166-82. PubMed ID: 20613720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovative approaches to clinical development and trial design.
    Orloff JJ; Stanski D
    Ann Ist Super Sanita; 2011; 47(1):8-13. PubMed ID: 21430331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation model-based drug discovery and development: quantitative and systems pharmacology.
    Allerheiligen SR
    Clin Pharmacol Ther; 2010 Jul; 88(1):135-7. PubMed ID: 20531467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of modeling and simulation in pediatric investigation plans.
    Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
    Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic advantage of pharmacogenomics - clinical trials with genetic information.
    Ohashi W; Mizushima H; Tanaka H
    Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
    Zhu L; Shi X; Liu Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal design of pharmacokinetic studies.
    Aarons L; Ogungbenro K
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):250-5. PubMed ID: 20102362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.
    Atkinson AJ; Lalonde RL
    Clin Pharmacol Ther; 2007 Jul; 82(1):3-6. PubMed ID: 17571065
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective.
    Chaikin P; Rhodes GR; Bruno R; Rohatagi S; Natarajan C
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1428-38. PubMed ID: 11185663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation of clinical trials.
    Holford NH; Kimko HC; Monteleone JP; Peck CC
    Annu Rev Pharmacol Toxicol; 2000; 40():209-34. PubMed ID: 10836134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients.
    Abbas I; Rovira J; Casanovas J; Greenfield T
    J Biomed Inform; 2008 Dec; 41(6):1053-61. PubMed ID: 18534916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences with learning and confirming in drug and biological development.
    Patterson SD
    Clin Pharmacol Ther; 2010 Aug; 88(2):161-3. PubMed ID: 20648033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of optimal design methodologies in clinical pharmacology experiments.
    Ogungbenro K; Dokoumetzidis A; Aarons L
    Pharm Stat; 2009; 8(3):239-52. PubMed ID: 19009585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.